MicroRNA-183-5p: A New Potential Marker for Prostate Cancer

We found that the expression of miR-183-5p in prostate cancer tissue was significantly up regulated as compared to benign prostatic hyperplasia patients and adjacent normal tissues as control

Mohammad Waseem


Scholarcy highlights

  • Prostate cancer is the most commonly diagnosed carcinoma after the age of 50 years in men
  • Serum prostate-specific antigen levels were significantly elevated in prostate cancer patients when compared with benign prostatic hyperplasia patients
  • High Expression of miR-183-5p in Tissue of PCa Patients Compared with BPH Patients and Adjacent Normal Control
  • During the last few years, specific miRNA signatures for PCa have been illustrated in numerous studies suggesting that miRNAs or miRNA profiles can be used as diagnostic markers in cancer including prostate cancer . miR183-5p is the most important among the miRNAs that has been shown to be differentially expression in several cancers, including breast cancer, colorectal cancer, prostate cancer . mir-183 is located on human chromosome 7q32.2 and forms a cluster with miR-96 and miR182
  • We observed the expression of miR-183-5p in tissue and determined that it was significantly up regulated in PCa patients compared to BPH and control, which revealed a strong association between PCa and miR-183-5p expression
  • The much higher expression of tissue miR-183-5p was identified in PCa patients with more aggressive tumors and with metastasis condition
  • MiR-183-5p over expression is increased with disease progression and in metastasis condition of prostate cancer. ROC analyses proved that mir-183-5p have quality to be used as diagnostic marker with good specificity and sensitivity

Need more features? Save interactive summary cards to your Scholarcy Library.